Tipranavir(tip ran’ ah veer)
AptivusDNC
PREGNANCY CATEGORY C
Drug Classes
Antiviral drug
Protease inhibitor
Therapeutic Actions
Inhibits virus specific processing of polyproteins, leading to the inability to produce mature virions and decreasing virus levels.
Indications
Along with ritonavir, as combination treatment of patients infected with HIV, with evidence of viral replication who are treatment-experienced or have HIV-1 strains resistant to more than one protease inhibitor
Contraindications and Cautions
Contraindicated with known hypersensitivity tipranavir or any of its components, moderate to severe hepatic insufficiency (Child-Pugh class B or C); administration with other drugs that are CYP3A inducers or that depend extensively on CYP3A for clearance.
Use cautiously with diabetes mellitus, hypergylcemia, known allergy to sulfonamides, hemophilia, hepatits B or C infection, pregnancy, lactation.
Available Forms
CapsulesDNC—250 mg; solution—100 mg/mL
Dosages
Adults
500 mg/day PO in combination with 200 mg ritonavir, taken with food.
Pediatric patients ages 2–18 yr
14 mg/kg with 6 mg/kg of ritonavir PO bid (375 mg/m2 with 150 mg/m2 ritonavir PO bid). Maximum dose, 500 mg with 200 mg ritonavir twice daily, taken with food.
Pharmacokinetics
Metabolism: Hepatic: T1/2: 4.8–6 hr
Distribution: May cross placenta; may pass into breast milk
Excretion: Feces, urine
Adverse Effects
CNS: Depression, insomnia, headache
GI: Nausea, vomiting, abdominal pain, diarrhea, potentially fatal liver impairment
Respiratory: Cough, bronchitis
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
